EP3463453A1 — Combination of pembrolizumab and abemaciclib for the treatment of cancer
Assigned to Organon Pharma UK Ltd · Expires 2019-04-10 · 7y expired
What this patent protects
The present invention relates to a combination of abemaciclib and pembrolizumab and methods of using the combination to treat certain disorders, such as breast cancer and non-small cell lung cancer.
USPTO Abstract
The present invention relates to a combination of abemaciclib and pembrolizumab and methods of using the combination to treat certain disorders, such as breast cancer and non-small cell lung cancer.
Drugs covered by this patent
- Verzenio (abemaciclib) · Eli Lilly
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.